• M Chen, T-C Tang, Y Wang, J Shui, X-H Xiao, X Lan, P Yu, C Zhang, S-H Wang, J Yao, H Zheng, and D-Q Huang.
• Clinical Medicine College/Teaching hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
• Aliment. Pharmacol. Ther. 2018 Jul 1; 48 (2): 160-168.

BackgroundTong-Xie-Yao-Fang (TXYF) is a Chinese herbal formula for treating chronic diarrhoea accompanied by abdominal pain. The results were inconsistent in previous trials examining its effect.AimTo study the efficacy of TXYF granules for treating diarrhoea-predominant irritable bowel syndrome (IBS-D).MethodsWe performed a double-blind, placebo-controlled randomised trial and enrolled 160 participants with IBS-D. The participants had VAS scores ≥3 cm in IBS-D global symptoms and ≥2 days in a week with abdominal pain and loose stools (Bristol score 5, 6 or 7). They were randomly assigned to received TXYF or placebo during a treatment period of 4 weeks, and they were followed up for 8 weeks after treatment. The primary outcome was adequate relief of IBS-D global symptoms for at least 2 of 4 weeks during weeks 1-4. Secondary outcomes included mean weekly VAS scores of IBS-D major symptoms, mean weekly stool frequency, mean weekly Bristol score, and adverse events.Results155 of 160 patients completed the trial. We found a significantly higher rate of adequate relief of global symptoms in TXFY group during weeks 1 to 4 (57.5% vs 37.5%, χ2 = 5.6391, P = 0.017); logistic regression analysis showed a similar result (OR 2.2, 95% CI 1.2-4.4, P = 0.016). Most of the secondary outcomes showed superiority of TXYF over placebo in weekly assessment from week 3 to week 7. The adverse event rate was low in both groups (3.8% vs 3.8%, P = 1.000).ConclusionDuring a 4 week trial, TXFY granules were superior to placebo in controlling symptoms of IBS-D.© 2018 John Wiley & Sons Ltd.

24 keywords...

hide…